3',5'-cyclic AMP(1-) : An organophosphate oxoanion that is the conjugate base of 3',5'-cyclic AMP arising from deprotonation of the free phosphate OH group; major species at pH 7.3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 7059571 |
| CHEBI ID | 58165 |
| MeSH ID | M0000378 |
| Synonym |
|---|
| smr000875274 |
| adenosine 3',5'-cyclic monophosphate sodium salt monohydrate |
| MLS001333136 , |
| adenosine cyclic-3',5'-monophosphate |
| adenosine-3',5'-monophosphate |
| 60-92-4 |
| cyclic-3',5'-adenosine monophosphate |
| adenosine-3',5'-cyclic monophosphate |
| cyclic-amp |
| (1s,6r,8r,9r)-8-(6-aminopurin-9-yl)-3-hydroxy-3-oxo-2,4,7-trioxa-3?5-phosphabicyclo[4.3.0]nonan-9-ol |
| 3CLP |
| 3',5'-cyclic amp anion |
| adenosine 3',5'-cyclic monophosphate anion |
| adenosine 3',5'-cyclic monophosphate(1-) |
| 3',5'-cyclic amp(1-) |
| CHEBI:58165 |
| (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-oxidanidyl-2-oxidanylidene-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol |
| A832959 |
| (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphorin-7-ol |
| (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol |
| 3U10 |
| 3OTF |
| 3OCP |
| 2K0G |
| sodium;(4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphorin-7-ol |
| sodium;(4ar,6r,7r,7as)-6-adenin-9-yl-2-keto-2-oxido-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphorin-7-ol |
| sodium;(4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-oxidanidyl-2-oxidanylidene-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol |
| cid_23669773 |
| bdbm81289 |
| NCGC00485221-01 |
| Q27125416 |
| DTXSID501214160 |
| 62906-31-4 |
| adenosine, cyclic 3',5'-(hydrogen phosphate), ion(1-) |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Role | Description |
|---|---|
| human metabolite | Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). |
| Saccharomyces cerevisiae metabolite | Any fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| organophosphate oxoanion | An organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Mll3241 protein | Mesorhizobium loti | Kd | 0.1070 | 0.1070 | 0.1070 | 0.1070 | AID977611 |
| Chain A, Mll3241 protein | unidentified | Kd | 205.1000 | 205.1000 | 205.1000 | 205.1000 | AID977611 |
| Chain A, PRKG1 protein | Homo sapiens (human) | Kd | 0.0270 | 0.0270 | 0.0270 | 0.0270 | AID977611 |
| Chain A, PRKG1 protein | Homo sapiens (human) | Kd | 0.0270 | 0.0270 | 0.0270 | 0.0270 | AID977611 |
| Chain A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Homo sapiens (human) | Kd | 0.8300 | 0.8300 | 0.8300 | 0.8300 | AID977611 |
| Chain A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2 | Homo sapiens (human) | Kd | 3.6000 | 3.6000 | 3.6000 | 3.6000 | AID977611 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2011 | PloS one, Apr-19, Volume: 6, Issue:4 | Co-crystal structures of PKG Iβ (92-227) with cGMP and cAMP reveal the molecular details of cyclic-nucleotide binding. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2010 | The Journal of biological chemistry, Nov-19, Volume: 285, Issue:47 | Structural basis for the cAMP-dependent gating in the human HCN4 channel. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2009 | EMBO reports, Jul, Volume: 10, Issue:7 | Solution structure of the Mesorhizobium loti K1 channel cyclic nucleotide-binding domain in complex with cAMP. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2011 | The Journal of biological chemistry, Dec-30, Volume: 286, Issue:52 | Tetramerization dynamics of C-terminal domain underlies isoform-specific cAMP gating in hyperpolarization-activated cyclic nucleotide-gated channels. |
| AID977611 | Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB | 2008 | Journal of molecular biology, Sep-05, Volume: 381, Issue:3 | Structural and energetic analysis of activation by a cyclic nucleotide binding domain. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||